Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 716

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 716
---
 | ​ | ​    | ​ | ​ | ​                     | ​ |   35,908 | ​ | ​ | ​ | ​                           | ​ | -78,503 | ​ | ​ | ​ | ​                                                          | ​ |   -100 | ​ | ​ | ​ | ​    | ​ | ​ | ​                       | ​ | -78,603 | ​ | ​ | ​ | ​                                               | ​ |   96,905 | ​ | ​ | ​ | ​    | ​ | ​ | ​                 | ​ |  54,210 | ​ | ​ |
| Total liabilities and stockholders’equity (deficit)                           | ​ | ​ | ​                         | $ |   51,329 | ​ | ​ | ​ | ​                                                                      | $ | -15,421 | ​ | ​ | ​ | ​    | ​ | ​ | ​                     | $ |   35,908 | ​ | ​ | ​ | ​                           | $ |  12,514 | ​ | ​ | ​ | ​                                                          | $ | 28,298 | ​ | ​ | ​ | ​    | ​ | ​ | ​                       | $ |  40,812 | ​ | ​ | ​ | ​                                               | $ |   -4,982 | ​ | ​ | ​ | ​    | ​ | ​ | ​                 | $ |  71,738 | ​ | ​ |
| ​                                                                             |   |   |                           |   |          |   |   |   |                                                                        |   |         |   |   |   |      |   |   |                       |   |          |   |   |   |                             |   |         |   |   |   |                                                            |   |        |   |   |   |      |   |   |                         |   |         |   |   |   |                                                 |   |          |   |   |   |      |   |   |                   |   |         |   |   |

See accompanying Notes to the Unaudited Pro Forma Condensed Combined Financial Information. 417

TABLE OF CONTENTS UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 (In thousands, except share and per share amounts)

| ​                                                                                          
 ​                                                                                          
 Revenue:                                                                                   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Historical                
 7(A